首页> 外文会议>World biomaterials congress >Cardiac derived ECM enhances cardiogenic properties of Human Cardiac Progenitor Cells
【24h】

Cardiac derived ECM enhances cardiogenic properties of Human Cardiac Progenitor Cells

机译:心脏衍生的ECM增强人心脏祖细胞的心形成特性

获取原文
获取外文期刊封面目录资料

摘要

Introduction: During the last few years, cardiac tissue engineering has emerged as a new therapeutic approach for the regeneration of the infarcted heart. Different factors can influence the success of a tissue engineering application, the most important of which are the choice of cells and matrix. The ideal matrix should promote cell engraftment, survival and differentiation of the transplanted cells as well as mimic the properties of the endogenous cardiac ECM. A porcine derived myocardial matrix hydrogel has been shown to improve cardiac function upon injection into an infarcted heart and to promote cardiogenesis in murine cardiac progenitor cells (mCPCs). However, its effect on clinically applicable human CPCs (hCPCs) still needs to be addressed. Materials, Methods and Results: In this study, we investigated the in vitro influence of the myocardial matrix hydrogel on the cardiogenic phenotype of Sca-1-like human derived CPCs. Human fetal and adult CPCs (hfCPCs and haCPCs) were isolated from heart biopsies and encapsulated in the myocardial matrix and compared to collagen type Ⅰ hydrogels. RT-PCR analysis of encapsulated hfCPCs displayed a significant increase in the cardiac transcription marker Gata-4 as well as in the sarcomeric protein MLC2v and the vascular marker VEGF receptor 2 (VEGF-R2) after 4 days in culture (n=6; p<0.05). Similarly increased levels were observed for early cardiac transcription factors Nkx2.5 and mef-2c as well as vascular markers VEGF-R2 and CD31 when haCPCs were cultured in the matrix compared to collagen (n=5; p<0.05). Cell viability was sustained in both hydrogels up to 1 week in culture, as showed by a cell viability assay. Hematoxylin and Eosin staining showed that the cells remain homogenously dispersed in the hydrogels, with increasing nuclear densities upon culturing. Interestingly, the myocardial matrix cultured human fetal and adult CPCs showed a significant increase in the proliferation marker Ki67 after 4 days in culture when compared to collagen group (n=6 and n=4 respectively; p<0.05). Cellular protein expression of Nkx2.5 and Tnl was also confirmed by immunofluorescence at day 4 and 7. Finally, to evaluate if the matrix is able to preserve CPCs viability, encapsulated CPCs were treated with 500 μM (hfCPCs) or 750 μM (haCPCs) H_2O_2 for 16 hours. Evaluation via Alamar blue assay showed an improved survival of encapsulated cells in the myocardial matrix when compared to the collagen matrix (n=9 and n=8 respectively; p<0.05). Conclusion: In summary, we showed that the myocardial matrix hydrogel is advantageous for hCPCs culture and encapsulation, enhancing CPCs proliferation, survival and cardiogenic potential compared to collagen. This work demonstrates the potential of the myocardial matrix as an in vitro platform and warrants its further investigation for cell transplantation in the diseased myocardium.
机译:介绍:在过去几年中,心脏组织工程作为一种新的梗死心脏再生治疗方法。不同的因素可以影响组织工程应用的成功,最重要的是哪些是细胞和基质的选择。理想的基质应促进移植细胞的细胞植入,存活和分化,以及模拟内源性心脏ECM的性质。已经证明了一种猪衍生的心肌基质水凝胶在注射到梗死的心脏并促进小鼠心脏祖细胞(MCPC)时改善心脏功能。然而,它对临床适用的人类CPC(HCPCS)的影响仍然需要解决。材料,方法和结果:在本研究中,我们研究了心肌基质水凝胶对SCA-1样的CPC的心形成表型的体外影响。人胎儿和成人CPC(HFCPC和HACPC)与心脏活组织检查分离,并在心肌基质中包封并与Ⅰ型水凝胶相比。包封的HFCPC的RT-PCR分析显示出心脏转录标记物GATA-4以及在培养4天后在培养蛋白MLC2V和血管标记VEGF受体2(VEGF-R2)中显着增加(n = 6; p <0.05)。对于早期心脏转录因子NKX2.5和MEF-2C以及血管标记物VEGF-R2和CD31,与胶原蛋白培养时,观察到血管标记物VEGF-R2和CD31(n = 5; p <0.05)。细胞活力在培养中的30至1周的水凝胶中持续,如细胞活力测定所示。苏木精和曙红染色表明,细胞在水凝胶中均匀分散在水凝胶中,随着培养后的核密度增加。有趣的是,与胶原基(n = 6和n = 4分别分别; P <0.05)相比,心肌基质培养的人胎儿和成人CPC在培养4天后显示出培养4天后的增殖标志物Ki67显着增加。在第4天和第7天的免疫荧光也证实了NKX2.5和TN1的细胞蛋白表达。最后,为了评估基质能够保持CPC活力,用500μM(HFCPC)或750μm(HACPC)处理包封的CPC H_2O_2 16小时。通过Alamar蓝色测定评价显示与胶原基质(n = 9和n = 8分别; P <0.05)时,肌肌型蓝色测定显示在心肌基质中包封细胞的提高存活。结论:总之,我们表明,与胶原蛋白相比,心肌基质水凝胶是有利于HCPC培养和包封,增强CPC的增殖,存活和心形成潜力。这项工作证明了心肌基质作为体外平台的潜力,并认证其进一步调查患病心肌中的细胞移植。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号